Participants used 5-point Likert scale responses (very uninterested to very interested) to indicate their interest in taking oral PrEP ("How interested are you in taking oral PrEP to prevent HIV?") and injectable PrEP ("How interested are you in taking injectable PrEP to prevent HIV?"). Responses of "interested" or "very interested" in either oral or injectable PrEP defined PrEP interest.
Mean score of 5-point Likert scale responses (strongly disagree to strongly agree) to 21 items measuring acceptability of OPPEN/control sessions among index participants where higher scores indicate greater acceptability (range: 1-5).
Mean score of 5-point Likert scale responses (strongly disagree to strongly agree) to 5 items measuring feasibility of OPPEN/control sessions among index participants where higher scores indicate greater feasibility (range: 1-5).
Group
Value
95% CI
OPPEN Index Participants
4.2
± 0.7
Control Index Participants
3.9
± 0.5
Acceptability of Interaction With Referring Index (Peer-Recruit Participants)Secondary· Baseline
Mean score of 5-point Likert scale responses (strongly disagree to strongly agree) to 9 items measuring the acceptability of the interaction with their peer (OPPEN or control index) when they referred them to the study among peer-recruit participants where higher scores indicate greater acceptability (range: 1-5).
Group
Value
95% CI
OPPEN Peer-Recruit Participants
4.7
± 0.4
Control Peer-Recruit Participants
3.6
± 0.8
Feasibility of Interaction With Referring Index (Peer-Recruit Participants)Secondary· Baseline
Mean score of 5-point Likert scale responses (strongly disagree to strongly agree) to 2 items measuring the feasibility of the interaction with their peer (OPPEN or control index) when they referred them to the study among peer-recruit participants where higher scores indicate greater feasibility (range: 1-5).
Group
Value
95% CI
OPPEN Peer-Recruit Participants
4.5
± 0.7
Control Peer-Recruit Participants
4.0
± 0.6
Sponsor's own description
Onboarding Positives and PrEP users to Engage Negatives (OPPEN) is an intervention to train young men who have sex with men (YMSM) of color living with HIV or using pre-exposure prophylaxis (PrEP) to promote PrEP use among HIV-negative YMSM of color in their social networks. This pilot randomized controlled trial will evaluate OPPEN's acceptability, feasibility, and preliminary effect on PrEP care engagement among YMSM of color.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor
· Phase 2
· recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
· Phase 2
· recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV
· NA
· recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i
· Phase 1
· recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
· Phase 1
· recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care
· NA
· not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease
· NA
· not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes
· Phase 3
· not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples
· NA
· not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2)
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05356910.